Biopharmaceuticals & biomedicines

01Overview and value chain#

Markers EC: 21.20 | OECD: bio-pharma | Regulator: FDA (US), EMA (EU), NMPA (CN)

Biopharmaceuticals are large, complex therapeutic molecules (proteins, antibodies, peptides) produced within living organisms rather than synthesized chemically. Relying on recombinant DNA technology and mammalian cell culture, these medicines target highly specific pathways, transforming the treatment of cancer, diabetes, and rare diseases. The global market, heavily driven by multi-billion-dollar blockbusters like GLP-1 agonists and monoclonal antibodies, relies on highly stringent regulatory oversight and massive capital investments in sterile biomanufacturing.

The key directions of biopharmaceuticals are:

1. Recombinant Proteins (Recombinant Proteins): replacing missing or defective human proteins, such as insulin (serving over 500 million diabetics globally).
2. Monoclonal Antibodies (Monoclonal Antibodies): highly targeted therapeutics for oncology and autoimmune disorders dominating the top-grossing drug charts.
3. Vaccines (Vaccines): biologically derived antigens (viral vectors, subunit proteins) driving global infectious disease prevention.
4. Biosimilars (Biosimilars): lower-cost, highly similar alternatives to off-patent biologic drugs, expanding patient access significantly.

Sectoral value chain#

[Discovery] ──> [Cell Line Dev] ──> [Bioprocessing] ──> [Purification]
                                  │
                          (Drug Substance)
                                  │
                                  ▼
[Patient Care] <─── [Fill & Finish] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Single-Use Technologies (SUT): utilizing disposable plastic bioreactor bags to eliminate cleaning validation and speed up batch changeovers.
• Continuous Biomanufacturing: transitioning from batch processing to continuous perfusion and chromatography to boost volumetric productivity.
• High-Throughput Process Analytical Technology (PAT): real-time, inline sensors monitoring cell health, titer, and protein folding quality.

02US#

The US is the undisputed engine of global biopharmaceutical innovation, fueled by massive biotech venture capital and premium drug pricing.

biotech innovation, monoclonal antibodies, FDA accelerated pathways#

• Regeneron R&D: leveraging human genetic databases to rapidly discover and commercialize novel targeted antibodies.
• Biogen Neurology: pioneering complex biologic therapeutics targeting neurodegenerative diseases like Alzheimer’s.
• Merck & Co (MSD): commercialized pembrolizumab (Keytruda), the world’s largest-selling immuno-oncology monoclonal antibody and a flagship of recombinant mammalian-cell biomanufacturing.
• Gilead Sciences: antiviral biologic leader (HIV, hepatitis) that extended into cell therapy through its Kite Pharma division.
• Bristol-Myers Squibb: immuno-oncology biologic franchise (Opdivo/nivolumab, Yervoy) built on large-scale monoclonal-antibody biomanufacturing.
• FDA Breakthrough Designation: providing expedited regulatory pathways to bring critical, life-saving biologics to market years earlier.

03CN#

China is aggressively expanding its biopharmaceutical footprint, moving rapidly from being a major contract manufacturing hub to an innovator of original therapeutics.

domestic innovation, oncology biologics, accelerated approval#

• BeiGene Global Expansion: aggressively developing and commercializing original oncology biologics for both domestic and international markets.
• Hengrui Medicine Shift: transitioning its massive legacy pharma portfolio heavily toward innovative large-molecule biologics.
• Innovent Biologics: Suzhou-based innovator of domestic PD-1 inhibitors and biosimilars, exporting oncology biologics under accelerated NMPA pathways.
• NMPA Regulatory Reforms: aligning domestic clinical trial standards with global ICH guidelines to fast-track novel biologics.

04EU#

The EU commands a legacy of deep biomanufacturing expertise and leads the world in metabolic disease therapeutics and vaccine production.

metabolic blockbusters, legacy biomanufacturing, biosimilar adoption#

• Novo Nordisk Dominance: driving unprecedented growth through its GLP-1 peptide therapeutics for diabetes and obesity.
• Sanofi Vaccine Platforms: scaling next-generation recombinant and mRNA platforms for global vaccine supply.
• EMA Biosimilar Framework: setting the global gold standard for the regulatory approval and widespread adoption of affordable biosimilars.

05Leading companies and research institutes#

06Tech stack and innovations#

Biopharmaceutical production requires an interplay of cellular engineering, fluid dynamics, and extreme sterility.

1. CHO Cell Expression Platforms:
   • Chinese Hamster Ovary (CHO) cells remain the industry workhorse, genetically engineered to secrete human proteins.
   • Advances in metabolic engineering have pushed fed-batch bioreactor titers well past 10 g/L.
2. Protein A Chromatography:
   • The cornerstone of downstream purification, using highly specific binding affinity to isolate monoclonal antibodies from complex cell culture broths.
   • Resin capacity and flow rates dictate the overall speed of the downstream bottleneck.
3. Lyophilization & Formulation:
   • Freeze-drying unstable protein therapeutics to extend shelf-life without degrading their complex 3D structures.
   • Developing advanced excipients to allow for subcutaneous self-injection rather than clinical intravenous infusions.

07Value chains and production pipelines#

Industrial pipeline of recombinant biomanufacturing (GMP Standards)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Cell bank expansion    │ ───> │ 2. Upstream cultivation   │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Downstream processing  │ <─── │ 3. Primary recovery       │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Formulation & fill     │ ───> │ 6. QC & dispatch          │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Cell bank expansion

Thawing a vial of genetically engineered cells from the cryogenic Master Cell Bank and expanding the culture through a series of increasingly larger seed flasks.

Stage 2: Upstream cultivation

Transferring the cells into production-scale bioreactors (up to 20,000 liters) where they multiply and secrete the target therapeutic protein over 10 to 21 days.

Stage 3: Primary recovery

Using industrial centrifugation and depth filtration to separate the living cells and debris from the nutrient broth containing the secreted proteins.

Stage 4: Downstream processing

Running the clarified broth through multiple highly specialized chromatography columns to isolate the target protein and achieve >99.9% purity.

Stage 5: Formulation & fill

Adding stabilizing buffers (excipients) to the pure drug substance and transferring it into sterile vials or auto-injector pens under stringent aseptic conditions.

Stage 6: QC & dispatch

Conducting rigorous release testing for sterility, protein folding integrity, and endotoxin limits before shipping via the pharmaceutical cold chain.